Literature DB >> 29223370

Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.

Anne L H Øvrehus1, Henrik Krarup2, Inge Birkemose3, Dorte K Holm4, Belinda Mössner5, Anja Ernst2, Peer B Christensen5.   

Abstract

Entities:  

Keywords:  Direct acting antivirals; Hepatitis C; Intra venous drug use; Randomized clinical trial; Treatment

Mesh：

Substances：

Year:  2017        PMID： 29223370     DOI： 10.1016/j.jhep.2017.11.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  6 in total

1.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

2.  The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.

Authors:  Peng Huang; Yan Wang; Ming Yue; Zhijun Ge; Xueshan Xia; Andre J Jeyarajan; Jacinta A Holmes; Rongbin Yu; Chuanwu Zhu; Sheng Yang; Wenyu Lin; Raymond T Chung
Journal:  Liver Int       Date:  2021-06-16       Impact factor: 8.754

3.  The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.

Authors:  Leanne McCabe; Ian R White; Nguyen Van Vinh Chau; Eleanor Barnes; Sarah L Pett; Graham S Cooke; A Sarah Walker
Journal:  Trials       Date:  2020-05-18       Impact factor: 2.279

Review 4.  Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.

Authors:  Xue Yang; Yang Tang; Di Xu; Guang Zhang; Peng Xu; Houlin Tang; Lin Pang
Journal:  Virol J       Date:  2021-07-27       Impact factor: 4.099

5.  Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.

Authors:  Lone W Madsen; Peer B Christensen; Janne F Hansen; Birgit T Røge; Dorte K Holm; Sandra Dröse; Anne Øvrehus
Journal:  Viruses       Date:  2022-03-16       Impact factor: 5.048

6.  Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis.

Authors:  Christopher R Jones; Barnaby F Flower; Ella Barber; Bryony Simmons; Graham S Cooke
Journal:  Wellcome Open Res       Date:  2019-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.